Mesothelioma is getting better with immunotherapy drug

Mesothelioma is a type of cancer that develops in the lining of the lungs and chest wall, it is causes by inhalation of asbestos fibre.

It is difficult to detect the cancer at early stage because their is no symptoms until it reach an advanced stage.

An immunotherapy drug,
Pembrolizumab seems to be effective in the treatment of mesothelioma.

First-line therapy is the standard treatment for mesothelioma, according to Dr.Evan Alley, researchers have studied different drugs but have not seen positive results.

Pembrolizumab is a checkpoint inhibitor, it is designed to fight cancer by defeating process that cancer cells use to avoid being destroyed by the immune system.

Common adverse effect of the drug are: dry mouth, nausea, fatigue, and loss of appetite.